What Makes CELMoDs Different from IMiDs
CELMoDs (Cereblon E3 Ligase Modulators) overcome IMiD resistance by binding cereblon (CRBN) — the substrate receptor of the CRL4CRBN E3 ubiquitin ligase complex — with greater affinity and selectivity than legacy agents such as thalidomide, lenalidomide, and pomalidomide. The result is deeper and more sustained degradation of two transcription factors essential for myeloma cell proliferation and survival: Ikaros (IKZF1) and Aiolos (IKZF3).
The mechanistic distinction is fundamental. Legacy IMiDs act as competitive modulators of CRBN substrate recognition. CELMoDs, by contrast, function as molecular glue degraders: the drug molecule simultaneously contacts both the E3 ligase and the target neosubstrate, physically bridging them to induce polyubiquitination and proteasomal degradation. This enables degradation of proteins otherwise considered undruggable through conventional inhibition strategies.
A molecular glue degrader is a small molecule that simultaneously contacts an E3 ubiquitin ligase and a target protein, physically bridging them to induce polyubiquitination and proteasomal degradation of the target. CELMoDs bridge CRL4CRBN to IKZF1/IKZF3, enabling degradation of these transcription factors in myeloma cells.
Iberdomide is explicitly characterized in retrieved clinical literature as “a novel, potent oral cereblon E3 ligase modulator (CELMoD™) with enhanced tumoricidal and immune-stimulatory effects compared with immunomodulatory drugs (IMiDs®).” Beyond direct myeloma cell killing via IKZF1/3 depletion, iberdomide activates T cells and NK cells in the tumor microenvironment — a dual mechanism that creates the rationale for synergistic combinations with anti-CD38 antibodies. According to the FDA, targeted protein degradation represents one of the most actively investigated modalities in oncology drug development.
Iberdomide is an oral cereblon E3 ligase modulator (CELMoD) that degrades the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) in myeloma cells with greater potency than IMiDs such as lenalidomide and pomalidomide, and has demonstrated in vitro synergy with dexamethasone, daratumumab, and bortezomib.
Mezigdomide (CC-92480), the second CELMoD in this pipeline, shares iberdomide’s CRBN-targeting mechanism but features a distinct chemical scaffold. Mezigdomide reportedly achieves faster and more complete IKZF1/3 degradation kinetics than iberdomide. Both agents are part of the CELMoD platform developed by Bristol-Myers Squibb/Celgene, though the retrieved patent dataset does not prominently capture direct BMS/Celgene CELMoD filings — reflecting dataset scope rather than any absence of IP activity.
Iberdomide in RRMM: From Phase 1/2 to EXCALIBER-RRMM Phase 3
Iberdomide’s clinical development in relapsed/refractory multiple myeloma is anchored by a Phase 1/2 trial that demonstrated antitumor activity with acceptable tolerability for the IberDd triplet (iberdomide plus daratumumab plus dexamethasone) — critically, including in patients refractory to both lenalidomide and pomalidomide. This IMiD-refractory activity is the central translational signal: enhanced CRBN engagement overcomes the resistance mechanisms of prior-generation agents.
The EXCALIBER-RRMM trial (NCT04975997) is a Phase 3, two-stage, randomized study comparing IberDd (iberdomide 1.6 mg daily on days 1–21 of 28-day cycles, plus daratumumab and dexamethasone) versus DVd (daratumumab, bortezomib, and dexamethasone) in patients with relapsed/refractory multiple myeloma, powered for progression-free survival superiority.
The Phase 1/2 predecessor data (Lonial S, et al., HemaSphere 2021;5(S2):S187) served as the basis for Phase 3 dose and regimen selection. The EXCALIBER-RRMM design — reported by Amsterdam University Medical Center and collaborating European institutions — represents the most mature CELMoD-specific clinical signal in the retrieved dataset, as of 2023 data.
“Iberdomide demonstrated antitumor activity with acceptable tolerability in IMiD-exposed RRMM patients, including patients refractory to lenalidomide and pomalidomide — indicating that enhanced CRBN engagement overcomes the resistance mechanisms of prior-generation agents.”
High-risk cytogenetic subgroups represent a critical unmet need within this patient population. The DEDALO Phase II trial (University of Perugia, 2023) confirmed that del(17p) clone size correlates with prognosis, and that TP53 biallelic inactivation defines “double-hit” MM with the worst outcomes. Retrieved results do not include direct CELMoD-specific data in del(17p) patients, representing both a knowledge gap and a development opportunity for pre-specified subgroup analyses in ongoing trials. As documented by the WHO, high-risk cytogenetics in plasma cell neoplasms continue to define a population with insufficient tailored treatment options globally.
Phase 1/2 data for IberDd (iberdomide + daratumumab + dexamethasone) demonstrated efficacy in RRMM patients refractory to both lenalidomide and pomalidomide. This positions iberdomide to serve the growing cohort of patients who have received lenalidomide-based frontline maintenance and exhausted prior IMiD options.
No direct clinical data on mezigdomide were captured in the retrieved dataset. Its absence reflects the search dataset’s limitations rather than a lack of clinical development activity — mezigdomide (CC-92480) is an active investigational agent with a distinct chemical scaffold and reportedly faster IKZF1/3 degradation kinetics than iberdomide.
Explore the full iberdomide and mezigdomide patent and literature landscape in PatSnap Eureka.
Search CELMoD Patents in PatSnap Eureka →Combination Strategies: CELMoD Triplets, Quadruplets, and Beyond
The RRMM field is moving toward quadruplet and even quintuplet regimens, and CELMoD combinations must demonstrate additive or synergistic efficacy alongside anti-CD38 antibodies, proteasome inhibitors, and potentially bispecific antibodies. Retrieved results identify three principal combination axes for iberdomide.
CELMoD + Anti-CD38 + Dexamethasone
The IberDd triplet tested in EXCALIBER-RRMM is the most mature combination approach in the retrieved dataset. The in vitro synergy between iberdomide, daratumumab, and dexamethasone is explicitly noted in retrieved abstracts: CELMoD-induced immune activation (T-cell and NK-cell priming) amplifies daratumumab’s antibody-dependent cellular cytotoxicity (ADCC) mechanism, while simultaneous Ikaros/Aiolos degradation directly kills myeloma cells. The comparator arm of EXCALIBER-RRMM — DVd (daratumumab, bortezomib, dexamethasone) — defines the clinical standard against which this triplet must demonstrate superiority.
CELMoD + Proteasome Inhibitor
Retrieved results note in vitro synergy between iberdomide and bortezomib, suggesting a pathway to future quadruplet regimens combining iberdomide, daratumumab, bortezomib, and dexamethasone. This combination logic is supported by the mechanistic complementarity of proteasome inhibition (blocking protein degradation globally) and targeted CRBN-mediated degradation of specific neosubstrates.
Sequencing with CAR-T and Bispecific Antibodies
Janssen Biotech’s patent filings (WO 2025, US 2026) describe combinations of anti-BCMA CAR-T cells with GPRC5D×CD3 bispecific antibodies in RRMM — a distinct modality operating through T-cell redirection. These cellular and biologic therapies now populate the later-line RRMM treatment algorithm, and CELMoDs may need to be evaluated either before or after these approaches, or potentially in combination, to leverage immune-stimulatory synergy. Research published in the New England Journal of Medicine has established CAR-T therapies as a benchmark for late-line response depth in RRMM.
MRD-Negativity as the Competitive Benchmark
Across retrieved results, MRD-negativity at 10⁻⁵ sensitivity is emerging as the gold-standard response endpoint in RRMM clinical development. Patent data from Janssen Biotech (US, 2023, active) specifically positions this threshold as a clinically meaningful endpoint in high-risk multiple myeloma treatment methods. Deep-sequencing MRD monitoring methods validated in Phase II trials (University Hospital Würzburg, 2017) underpin this endpoint framework. CELMoD combinations capable of achieving high MRD-negativity rates will compete favorably against CAR-T and bispecific antibody regimens, which currently set the benchmark for response depth in late-line settings.
MRD-negativity at 10⁻⁵ sensitivity is emerging as the gold-standard response endpoint in relapsed/refractory multiple myeloma clinical development; Janssen Biotech patent data (US, 2023) specifically positions this threshold as a clinically meaningful endpoint in high-risk multiple myeloma treatment methods.
Track MRD endpoint patents and CELMoD combination filings across jurisdictions with PatSnap Eureka.
Explore RRMM Patent Data in PatSnap Eureka →Patent Landscape: Who Holds the IP in RRMM
The retrieved patent landscape for RRMM is dominated by commercial IP activity from Sanofi-Aventis and Janssen Biotech, with academic institutions contributing mechanistically upstream patents relevant to CELMoD patient selection. CELMoD-specific IP from Bristol-Myers Squibb/Celgene is not prominently represented in the retrieved dataset, reflecting search scope limitations rather than the absence of a substantial proprietary position.
Sanofi-Aventis: Isatuximab Portfolio
Sanofi-Aventis U.S. LLC holds multiple active and pending patents covering isatuximab (anti-CD38) in RRMM and newly diagnosed multiple myeloma, spanning jurisdictions including Israel, India, Singapore, Mexico, Canada, and Japan (2021–2022). These filings cover isatuximab as a standalone agent and in combination with carfilzomib, pomalidomide, lenalidomide, bortezomib, and dexamethasone — framing the competitive therapeutic backdrop into which CELMoDs must be positioned.
Janssen Biotech: Daratumumab, CAR-T, and MRD
Janssen Biotech’s retrieved patent portfolio spans daratumumab combinations, BCMA-directed CAR-T cells combined with GPRC5D×CD3 bispecific antibodies (WO 2025, US 2026), and high-risk multiple myeloma treatment methods with MRD-negativity endpoints (US 2023). Daratumumab is the co-agent in EXCALIBER-RRMM, making Janssen simultaneously a competitive IP holder and a clinical collaboration partner in the CELMoD development story. According to the European Medicines Agency, daratumumab-based regimens are approved across multiple lines of multiple myeloma therapy in the EU.
Carolinas Healthcare System: IMiD Resistance and MRD Monitoring
The Charlotte Mecklenburg Hospital Authority (Carolinas Healthcare System) holds active US patents covering methods for determining IMiD resistance in plasma cell disorders (2018) and immune profiling for MRD monitoring post-stem cell transplantation (2018). These academic patents are directly upstream of CELMoD patient selection logic: if classical IMiDs fail due to CRBN mutation or reduced IKZF1/3 degradation efficiency, CELMoDs — designed with higher CRBN binding affinity — are positioned as the pharmacological solution. IP strategists should monitor CRBN binding mode and neosubstrate selectivity claims as the defining IP space for this class. PatSnap’s patent analytics platform provides landscape mapping across these intersecting IP domains.
Strategic Implications for the CELMoD Pipeline
The CELMoD pipeline faces a well-defined set of strategic imperatives: proving superiority over established daratumumab-based standards, achieving MRD-negativity benchmarks set by cellular therapies, and addressing high-risk cytogenetic subgroups where current options remain inadequate. Retrieved results crystallize five actionable strategic signals.
- IMiD-refractory patient capture: Retrieved results confirm iberdomide activity in patients refractory to lenalidomide and pomalidomide. This positions the CELMoD class to serve the growing cohort who have received lenalidomide-based frontline maintenance and exhausted prior IMiD options. The Greek Myeloma Study Group real-world dataset (725 RRMM patients, EHA 2023) highlights that second-line treatment decisions post-lenalidomide maintenance are increasingly consequential for post-progression outcomes.
- EXCALIBER-RRMM as the pivotal readout: The Phase 3 head-to-head design of IberDd versus DVd establishes a potential regulatory approval path for iberdomide. The trial is powered for progression-free survival superiority; approval in this indication would create a substantial commercial opportunity given the size of the 1–3 prior lines RRMM population.
- Combination depth as differentiation: Retrieved results show the RRMM field moving toward quadruplet regimens. CELMoD developers must demonstrate additive or synergistic efficacy in combination with anti-CD38 antibodies, proteasome inhibitors, and potentially bispecifics. The in vitro synergy data cited in EXCALIBER-RRMM abstracts provides the mechanistic foundation; clinical validation is the outstanding requirement.
- MRD-negativity as competitive positioning: CELMoD combinations achieving high rates of MRD-negativity at 10⁻⁵ will compete favorably against CAR-T and bispecific antibody regimens, which currently set the benchmark in late-line settings.
- High-risk cytogenetics as an unmet opportunity: Del(17p) and 1q-amplified MM are flagged across multiple retrieved clinical reports as populations with insufficient tailored treatment options. Retrieved results do not include direct CELMoD data in these subgroups — representing a clinical development opportunity for iberdomide and mezigdomide trials to address through pre-specified subgroup analyses.
Del(17p) and TP53 biallelic inactivation (“double-hit” multiple myeloma) define a high-risk cytogenetic subgroup with the worst clinical outcomes in relapsed/refractory multiple myeloma; retrieved clinical data (DEDALO Phase II trial, University of Perugia, 2023) confirm that del(17p) clone size correlates with prognosis, and no CELMoD-specific data in this subgroup has yet been captured in the clinical literature.